KARLEY MOORE: Open Payments
NPI 1114520491 · MANILA, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$393 in 19 payments from 12 companies in 2025. Trend: 2023 $337 · 2024 $398 · 2025 $393
Food & beverage: $393
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 3 | $70 |
| ABBVIE INC. | 3 | $67 |
| AstraZeneca Pharmaceuticals LP | 2 | $50 |
| Novo Nordisk Inc | 3 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Medtronic, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $15 |
Products named: Auvelity, CAPLYTA, Ozempic, FARXIGA, QULIPTA, GEMTESA, AIRSUPRA, VRAYLAR.
Industry payments across AR — which companies pay providers there.
